Olpadronate prevents thyroid hormone-induced cortical and trabecular bone loss in ovariectomized rats;El olpadronato previene la perdida de hueso cortical y trabecular inducida por dosis suprafisiologicas de tiroxina en ratas ovariectomizadas

Medicina

Volumn 58, Issue 5 I, 1998, Pages 453-457

  Zeni, Susana N ^a   Acotto, Claudia Gomez ^a   Di Gregorio, Silvana ^a  

^a HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

Author keywords

Bone mineral density; Olpadronate; Osteopenia; Ovanectomy; Thyroxine

Indexed keywords

OLPADRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; THYROXINE;

ANIMAL EXPERIMENT; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MASS; CONTROLLED STUDY; CORTICAL BONE; FEMALE; NONHUMAN; OSTEOPENIA; OVARIECTOMY; RAT; TRABECULAR BONE; ANIMAL; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; OSTEOPOROSIS; SPRAGUE DAWLEY RAT;

ANIMALS; BONE DENSITY; DIPHOSPHONATES; FEMALE; OSTEOPOROSIS; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; THYROXINE;

EID: 0031739132     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Mosekilde L. Eriksen EF, Charles P. Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin NA 1990; 19: 35-63.
2. Mosekilde L, Melsen F. A tetracycline-based histomorphometric evaluation of bone resorption and bone turnover in hyperthyroidism and hyperparathyroidism. Acta Med Scand 1978; 204: 97-102
3. Baran DT, Braverman LE. Thyroid hormones and bone mass. Editorial. J Clin Endocrinol Metab 1991; 71: 1182-3.
4. Meunier PJ, Bianchi GGS, Edouard CM, Bernard JC, Courpron P, Vignon GE. Bony manifestations of thyrotoxicosis. Orthop Clin NA 1972; 3: 745-74.
5. Adlin EV, Maurer AH, Marks AD, Channick BJ. Bone mineral density in postmenopausal women treated with L-thyroxine. Am J Med 1991; 90: 360-6.
6. Stall GM, Harris S, Sokoll LJ, Dawson-Hughes B. Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine. Ann Intern Med 1990; 113: 265-9.
7. Taelam P, Kaufman JM, Janssens X, Vandercauter H, Vermeulen A. Reduced forearm bone mineral content and biochemical evidence of increased bone turnover in women with euthyroid goiter treated with thyroid hormone. Clin Endocrinol 1990; 33: 107-17.
8. Rosen HN, Middlebrooks VL, Sullivan EK, Rosenblatt M, Maitland LA, Moses AC et al. Subregion analysis of the rat femur: a sensitive indicator of changes in bone density following treatment with thyroid hormone or bisphosphonates. Calcif Tissue Int 1994; 55: 173-5.
9. Zeni SN, Gómez Acotto C, Mautalen C. Olpadronate prevent thyroxine induced-osteopenia in OVX rats. Bone 1997; 21: 329-33.
10. Fleisch H. Bisphosphonates in bone disease. From the laboratory to the patient. 2nd. ed. New York: The Parthenon Publishing Group 1995; p 45.
11. Yamamoto M, Markatos A, Seedor JG, Masarachia P, Gentile M, Rodan G. et al. The effects of the aminobisphosphonate Alendronate on thyroid hormone-induced osteopenia in rats. Calcif Tissue Int 1993; 53: 278-82.
12. Fromm GA, Vega E, Plantalech L, Galich AM, Mautalen CA. Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis. Osteoporosis Int 1991; 1: 129.
13. Mautalen CA, González D, Ghiringhelli G. Efficacy of the bisphosphonate APD i nthe control of Paget's bone disease. Bone 1985; 6: 429.
14. Bickerstaff DR, O'Doherty DP, McCloskey EV, Hamdy NA, Mian M, Kanis JA. Effects of amino-butylidene disphosphonate in hypercalcemia due to malignancy. Bone 1991; 12: 17-20.
15. Schenk R, Eggli P, Fleisch H, Rosini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tiss Int 1986; 38: 42-9.
16. Bonekamp PM, Lowick CW, van der Wee-Pals LJ, van Wijk-van Lennep ML, Bijvoet OL. Enhancement of the inhibitoy action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group. Bone Miner 1987; 2: 29-42
17. Papapoulos SE, van Holten-Verzantvoort AT. Modulation of tumor-induced bone resorption by bisphosphonates. J Steroid Biochem Mol Biol 1992; 43: 131-6.
18. Frost HM, Jee WSS. On the rat model of human osteopenias and osteoporoses. Bone Miner 1992; 18: 227-36.
19. Reeve J. Bone turnover and trabecular plate survival after artificial menopause. Br Med J Clin Res 1987; 295: 757-60.
20. Stepan JJ, Pospichal J, Schreiber V, Kanka J, Mensik J, Presl J, et al. The application of plasma tartrate-resistant acid phosphatase to assess changes in bone resorption in response to artificial menopause and its treatment with estrogen or norethisterone. Calcif Tissue Int 1989; 45: 273-80.
21. Uebelhart D, Schlemmer A, Johansen JS, Bineyts E, Christiansen C, Delmas PD. Effect of menopause replacement therapy on the urinary excretion of pyndinium cross-links. J Clin Endocrinol Metab 1991; 72: 367-73.
22. Kelly PJ, Pocock NA, Sambrook PN, Eisman JA. Age and menopause-related changes in indices of bone turnover. Endocrinol Metab Clin NA 1989; 69: 1160-5.
23. Wronski TJ, Lowry PL, Walsh CC, Ignaszewki LA. Skeletal alterations in ovariectomized rats. Calcif Tissue Int 1985; 37: 324-8.
24. Wronski TJ, Walsh CC, Ignaszewki LA. Histological evidence for osteopenia and increased bone turnover in ovariectomized rats. Bone 1986; 7: 119-23.
25. Kalu DN. The ovariectomized rat model of postmenopausal bone loss. Bone Miner 1991; 15: 175-92.
26. Diamont T, Nevy I, Hales I. A therapeutic dilemma: Suppresive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab 1991; 72: 1184.8.
27. Wronski TJ, Dann LM, Horner SL. Time course of vertebral osteopenia in ovariectomized rats. Bone 1989; 10: 295-301.
28. Balena R, Markatos A, Gentile M, Masarachia P, Seedor JG, Rodan GA, et al. The aminobisphosphonate alendronate inhibits bone loss induced by thyroid hormone in the rat: comparison between effects on tibiae and vertebrae. Bone 1993; 14: 499-504.
29. Faber J, Galloc AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroixine treatment: a meta-analysis Eur J Endocrinol 1994; 130: 350-6.
30. Meema HE, Schatz DL. Simple radiological demonstration of cortical bone loss in thyrotoxicosis. Radiology 1970; 97: 9-15.
31. Yamaura M, Nakamura T, Kanou A, Miura T, Ohara H, Suzuki K. The effect of 17β-estradiol treatment on the mass and the turnover of bone in ovariectomized rats taking a mild dose of thyroxin. Bone Miner 1994; 24: 33-42.
32. Ongphiphadhanakul B, Jenis L, Braverman L, Alex S, Stein G, Lian J. et al Etidronate inhibits the thyroid hormone-induced bone loss in rats assessed by bone mineral density and messegerribonucleic acid markers of osteoblast and osteoclast function. Endocrinology 1993; 133: 2502-7.
33. Ongphiphadhanakul B, Alex S, Braverman L, Baran D. Excessive L-thyroxine Therapy decreases femoral bone mineral densities in the male rat: Effect of hypogonadism and calcitonin. J Bone Miner Res 1992; 7: 1227-31.
34. Rosen H, Sullivan E, Middlebrooks L, Zeind A, Gundberg C, Dresner-Pollak R et al. Parenteral pamidronate prevents thyroid hormone-induce bone loss in rats. J Bone Min Res 1993; 8: 1255-61.
35. Fleisch H. Bisphosphonates: pharmacology and use in the treatment of tumor induced hypercalcemic and metastatic bone disease. Drugs 1991; 42: 919-44.